Skip to content
Respana Therapeutics Inc.
Market/Category
Influenza Pneumonia – Therapeutic
Principal Investigator(s) and Department
Clinical Problem
Lower respiratory infections remain the deadliest communicable disease, causing 3.2 million deaths worldwide in 2015.
Survival of a lower respiratory infection can leave a patient with lifetime chronic pulmonary conditions.
Therapeutic Solution
Enhances eradication of the influenza virus, post-influenza pneumonia infections.
Decreases harmful inflammation that may lead to hypoxia.
Promotes recovery of respiratory function.
Reduces the risk of developing secondary bacterial infections in the respiratory system.